News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IntelGenx Corp. And RedHill Biopharma Ltd. (RDHL) Announce Commencement Of A Bioavailability Study With Anti-Migraine Versafilm™ Product To Support European Marketing Application Planned For Q3/2014


4/28/2014 9:10:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAINT LAURENT, Quebec, April 28, 2014 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focused on oral drug delivery, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, today announced the commencement of a comparative bioavailability clinical study comparing their anti-migraine VersaFilmâ„¢ Product to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application ("MAA") for the anti-migraine VersaFilmâ„¢ Product, a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Migraine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES